These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5013063)

  • 1. On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid.
    Rinne UK; Sonninen V; Hyyppä M
    Experientia; 1972 Jan; 28(1):57-9. PubMed ID: 5013063
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
    Jones DG; Turnbull MJ; Lenman JA; Robertson MA
    J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
    Jones DG; Lenman JA; Robertson MA; Turnbull MJ
    Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
    [No Abstract]   [Full Text] [Related]  

  • 4. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
    Rinne UK; Sonninen V
    Neurology; 1972 Jan; 22(1):62-7. PubMed ID: 4550499
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
    Parkes JD; Baxter RC; Curzon G; Knill-Jones RP; Knott PJ; Marsden CD; Tattersall R; Vollum D
    Lancet; 1971 May; 1(7709):1083-6. PubMed ID: 4102620
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B; Danta G; Schnieden H; Yuill GM
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of parkinsonism by amantadine and levodopa.
    Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE
    Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.
    Moir AT; Ashcroft GW; Crawford TB; Eccleston D; Guldberg HC
    Brain; 1970; 93(2):357-68. PubMed ID: 4912291
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitivity studies of L-dopa metabolites in reserpinized rats and their clinical significance.
    Ericsson AD; Wertman BG
    Neurology; 1971 Nov; 21(11):1129-33. PubMed ID: 5166218
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 13. [Experimental and clinical data on the mechanism of action of amantadine and on its effectiveness in Parkinson's disease].
    Beani L; Bianchi C; Gomirato G; Perfetti C; Cartei M
    Minerva Med; 1971 Oct; 62(82):3948-51. PubMed ID: 5125048
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of anesthetic doses of hydroxybutyrate on subcortical concentrations of homovanillic acid.
    Roth RH
    Eur J Pharmacol; 1971 Jun; 15(1):52-9. PubMed ID: 5161341
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 16. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 17. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experience in the prolonged use of midantan (amantadine hydrochloride) in parkinsonism].
    Man'kovskii NB; Vainshtok AB; Oleinik LI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):524-30. PubMed ID: 4705407
    [No Abstract]   [Full Text] [Related]  

  • 19. Accumulation of 3H-homovanillic acid in rabbit brain and cerebrospinal fluid following intravenous 3H-L-dopa.
    Extein I; Roth RH; Bowers MB
    Biol Psychiatry; 1974 Oct; 9(2):161-70. PubMed ID: 4429746
    [No Abstract]   [Full Text] [Related]  

  • 20. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
    Brogden RN; Speight TM; Avery GS
    Drugs; 1971; 2(4):262-400. PubMed ID: 4340597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.